Paasa Logo
Hanall Biopharma Co., Ltd. logo
009420KRXMarket closedOpens 9:00am KST

Hanall Biopharma Co., Ltd.

₩44,000.00Last updated
-₩1,800.00 (3.93%)Past day
Timezone

Hanall Biopharma Co., Ltd. (KRX: 009420) is trading at ₩44,000.00, about ₹3,176 at today's KRW/INR rate, as of 8 Oct 2026, 2:30 AM ET, down 3.93% today. Hanall Biopharma is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.

Quote

Open:₩45,050.00
Previous close:₩45,800.00
Volume:234.51K

Today's low

₩43,650.00

Today's high

₩45,200.00

52 week low

₩32,600.00

52 week high

₩73,000.00

009420 opened at ₩45,050.00, closed previously at ₩45,800.00, and has traded between ₩32,600.00 and ₩73,000.00 over the past 52 weeks.

About

HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceuticals. It offers products such as medicine for digestion, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives, and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.

Country
KR
CEO
Su-Jin Park
Exchange listed on
KRX
Industry
Medical - Pharmaceuticals
Base currency
KRW
Full Time Employees
315
Sector
Healthcare
IPO date
04/01/2000

Key statistics

Avg. volume

476.21K

Market cap

₩2.24T

P/E Ratio

-91.27

Price-to-sales ratio

13.76

Enterprise value

₩2.19T

Free cash flow yield

-0.15%

Debt-to-equity ratio

0.28

Return on equity

-3.44%

ROIC

-0.74%

Beta

0.88

Dividend yield

0.00%

Last dividend

₩0.00

Financial overview

Revenue

₩155.18B

Earnings per share

-₩111.55

Free cash flow

-₩3.29B

Net profit margin

-15.31%

Gross margin

52.08%

EBITDA

₩1.94B

Revenue growth

11.69%

Similar securities

This is not an investment recommendation

Hanall Biopharma for Indian investors

Hanall Biopharma is listed on the Korea Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.

Taxes on Hanall Biopharma for Indian residents

Trading and limits

Trading hours
9:00 am – 3:30 pm KST
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneHanall Biopharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained

FAQs

Can I buy Hanall Biopharma on Paasa?

Hanall Biopharma (009420) has been listed on the Korea Exchange since 2000, in the Medical - Pharmaceuticals industry. Hanall Biopharma is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.

How much does one Hanall Biopharma share cost in rupees?

One Hanall Biopharma share is ₩44,000.00 — about ₹3,176 at a KRW/INR rate of 0.0722 on 8 Oct 2026. Both the Hanall Biopharma price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for investing abroad from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.

How are gains on Hanall Biopharma shares taxed in India?

Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the KRW/INR rate on the purchase and the sale date, so the rupee move counts alongside the Hanall Biopharma price.

Does Hanall Biopharma pay a dividend?

No. Hanall Biopharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one: dividends are taxed at your slab rate in India.

When does KRX trade, in Indian time?

The Korea Exchange trades 5:30 am – 12:00 pm IST in Indian time.

Do I have to declare Hanall Biopharma shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.

Does the rupee rate affect what I make on Hanall Biopharma?

Yes. Hanall Biopharma is priced in KRW, so your rupee outcome combines the KRW move with the KRW/INR move between the day you remit and the day you convert back.